83881-52-1
83881-52-1 結構式
基本信息
鹽酸西替利嗪
西替利嗪
鹽酸西替立嗪
(+/-)-2-[2-[4-[(4-氯苯基)苯甲基]-1-哌嗪基]乙氧基]乙酸二鹽酸鹽
AKOS 92015
CETIRIZIN DIHYDROCHLORIDE
CETIRIZINE 2HCL
CETIRIZINE DI HCL
CETIRIZINE DIHYDROCHLORIDE
CETIRIZINE HCL
CETIRIZINE HYDROCHLORIDE
ZYRTEC
(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)aceticaciddihydro
(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-aceticacidihyd
ucb-p071
(±)-2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid,dihydrochloride
Cetirazine dihydrochloride
[2-[4-[(4-Chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic Acid, Dihydrochloride
Certirizine
CETIRZINE HYDROCHLORIDE
[83881-51-0], C21H25ClN2O3,388.89
1-piperazinyl]ethoxy]-,dihydrochloride
Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-
物理化學性質
常見問題列表
鹽酸西替利嗪適用于呼吸系統(tǒng)、皮膚和眼部過敏性疾病，包括常年性變態(tài)反應性疾病，如過敏性皮膚病、尋麻疹、過敏性鼻炎、眼瘙癢、眼結膜炎和哮喘等。
本品還用于治療各種類型皮膚科過敏性疾病。如用于慢性、人工性、寒冷性、遲發(fā)壓力性、日光性尋麻疹及異位皮炎等的治療。
本品還是蚊蟲叮咬引起的速發(fā)性風團和速發(fā)性丘團及瘙癢的有效藥物。
鹽酸西替利嗪不良反應一般輕微，有困倦、嗜睡、頭痛、眩暈、激動、口干及胃腸道不適等。偶有天門冬氨酸氨基轉移酶輕度升高。
嚴重的不良反應有：動眼神經(jīng)危象，表現(xiàn)為兩眼向上或向一側竄動的不自主眼肌痙攣動作等癥狀。
使用鹽酸西替利嗪口服劑型可能會發(fā)生嗜睡、眩暈，司機及從事危險操作者應謹慎使用。
西替利嗪的有效成分旋西替利嗪是鹽酸西替利嗪的光學異構體之一（左旋體）。ChemicalBook andy 整理編輯。
| Target | Value |
| Histamine receptor |
Cetirizine (>5 μM) at higher concentrations can reduce the release of GM-CSF and IL-8 from A549 cells stimulated with IL-1β. Cetirizine exerts anti-inflammatory effects beyond histamine H1-receptor antagonist [2] .
Cell Viability Assay [2]
| Cell Line: | Human airway epithelial cell line A549. |
| Concentration: | 0-10 μM. |
| Incubation Time: | 24 h. |
| Result: |
The survival of A549 cells incubated with various concentrations of cetirizine (0.1, 1, 2.5, 5, and 10 μM) for 24 hours were all higher than 90% when comparing with the control group by MTT test.
Cetirizine, 5 and 10 μM, suppressed GM-CSF release by 70.71 and 61.55%, respectively. Preincubation with cetirizine, 10 μM, suppressed the IL-8 secretion by 75.04%. |
Cetirizine (20 mg/kg, mice, orally) exerts its anti-inflammatory effects by inhibiting MIF as well as IL-8 production in mice immunized and challenged with ragweed pollen [3] .
| Animal Model: | Male 8-week-old BALB/c mice (25-30 g) immunized and challenged with ragweed pollen [3] . |
| Dosage: | 2 or 20 mg/kg. |
| Administration: | Orally, diluted in sterile water on days 18, 19, and 20. |
| Result: | The neutrophilia at 8 h and eosinophilia at 24 h induced by ragweed pollen extract per os were significantly reduced in the mice treated with 20 mg/kg. The dosage with 2 mg/kg had no effect. |